| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| LANGE LOUIS G | Director | C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS | /s/ Louise Kooij by Power of Attorney from Louis G. Lange | 10 Mar 2026 | 0001238401 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Ordinary Shares | Sale | $828,950 | -28,186 | -100% | $29.41 | 0 | 06 Mar 2026 | See footnote | F1, F2 |
| transaction | NAMS | Ordinary Shares | Exercise of in-the-money or at-the-money derivative security | +44,619 | +431% | $11.50* | 54,979 | 09 Mar 2026 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Warrant (right to buy) | Exercise of in-the-money or at-the-money derivative security | -44,619 | -100% | $0.000000* | 0 | 09 Mar 2026 | Ordinary Shares | 44,619 | $11.50 | Direct |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F2 | The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. |